NCT04186845 2025-09-22
Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence
Blue Earth Diagnostics
Phase 3 Completed
Clinical Trials
4 trialsNCT04186819 2025-02-26
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
Blue Earth Diagnostics
Phase 3 Completed
NCT04028388 2024-04-17
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
Modra Pharmaceuticals
Phase 2 Completed
NCT00918281 2014-06-09
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
GE Healthcare
Phase 2 Completed